Göbel, Sven http://orcid.org/0000-0002-2264-5569
Pelz, Lars http://orcid.org/0000-0001-7848-2298
Silva, Cristina A. T.
Brühlmann, Béla
Hill, Charles
Altomonte, Jennifer http://orcid.org/0000-0003-1079-3633
Kamen, Amine http://orcid.org/0000-0001-9110-8815
Reichl, Udo http://orcid.org/0000-0001-6538-1332
Genzel, Yvonne http://orcid.org/0000-0002-2652-5943
Funding for this research was provided by:
Max Planck Institute for Dynamics of Complex Technical Systems (MPI Magdeburg)
Article History
Received: 17 October 2023
Revised: 14 February 2024
Accepted: 16 February 2024
First Online: 27 February 2024
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Not applicable.
: Not applicable.
: J. Altomonte (WO 2017/198779) holds a patent for the development and use of rVSV-NDV as an oncolytic therapy of cancer and is co-founder of Fusix Biotech GmbH, which is developing the rVSV-NDV technology for clinical use. B. Brühlmann and C.Hill are employees of Repligen where the Krosflo TFDF system has been developed.